13- and 14-membered macrocyclic ligands containing methylcarboxylate or methylphosphonate pendant arms: Chemical and biological evaluation of their 153Sm and 166Ho complexes as potential agents for therapy or bone pain palliation

2006 ◽  
Vol 100 (2) ◽  
pp. 270-280 ◽  
Author(s):  
Fernanda Marques ◽  
Lurdes Gano ◽  
M. Paula Campello ◽  
Sara Lacerda ◽  
Isabel Santos ◽  
...  
2004 ◽  
Vol 25 (12) ◽  
pp. 1169-1176 ◽  
Author(s):  
Sudipta Chakraborty ◽  
Tapas Das ◽  
Sharmila Banerjee ◽  
Pradip R. Chaudhari ◽  
Haladhar Dev Sarma ◽  
...  

2016 ◽  
Vol 309 (3) ◽  
pp. 1183-1190
Author(s):  
Mahdokht Vaez-Tehrani ◽  
Samaneh Zolghadri ◽  
Hossein Afarideh ◽  
Hassan Yousefnia

2001 ◽  
Vol 66 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rosa Sciuto ◽  
Anna Festa ◽  
Rosella Pasqualoni ◽  
Alessandro Semprebene ◽  
Sandra Rea ◽  
...  

2016 ◽  
Vol 60 (1) ◽  
pp. 20-29
Author(s):  
Nafise Salek ◽  
Mohsen Mehrabi ◽  
Simindokht Shirvani Arani ◽  
Ali Bahrami Samani ◽  
Mostafa Erfani ◽  
...  

2020 ◽  
Vol 9 (8) ◽  
pp. 2622 ◽  
Author(s):  
Reyhaneh Manafi-Farid ◽  
Fardad Masoumi ◽  
Ghasemali Divband ◽  
Bahare Saidi ◽  
Bahar Ataeinia ◽  
...  

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other therapies. Several β¯- and α-emitters as well as pharmaceuticals, from the very first [89Sr]strontium-dichloride to recently introduced [223Ra]radium-dichloride, are investigated to identify an optimum agent. In addition, the combination of bone-seeking radiopharmaceuticals with chemotherapy or radiotherapy has been employed to enhance the outcome. Radiopharmaceuticals demonstrate an acceptable response rate in pain relief. Nevertheless, survival benefits have been documented in only a limited number of studies. In this review, we provide an overview of bone-seeking radiopharmaceuticals used for bone-pain palliation, their effectiveness and toxicity, as well as the results of the combination with other therapies. Bone-pain palliation with radiopharmaceuticals has been employed for eight decades. However, there are still new aspects yet to be established.


2015 ◽  
Vol 9 (1) ◽  
pp. 85-93 ◽  
Author(s):  
Henia Balter ◽  
Trindade Victoria ◽  
Terán Mariella ◽  
Gaudiano Javier ◽  
Ferrando Rodolfo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document